European Pharmaceutical Review

MARCH 6, 2023

The application was accepted by the European Medicines Agency (EMA) on 26 January, signalling another significant breakthrough for both patients and experts working to address the disease. Building on these 4R’s, we designed the Phase III Clarity AD study in order to definitively assess the safety and efficacy of lecanemab.

Food and Drug Administration 96

Food and Drug Administration Safety Medicine Pharmaceutical 96

Pharmaceutical Technology

FEBRUARY 3, 2023

Once a patient is infected with HIV, they are infected for life, except for a few rare cases, he says. Since this is a first-in-human study, the vaccine’s safety profile still needs to be understood, which explains why the first two cohorts received low doses, says Deeks. The third cohort features the highest studied dose.

Medicine 117

Medicine Prospecting Safety Manufacturing 117

European Pharmaceutical Review

DECEMBER 19, 2022

3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. For this reason, a unique ‘abridged’ procedure was introduced to provide a specific regulatory pathway for biosimilars in the EU.

Medicine 52

Medicine Biopharma Safety Food 52

pharmaphorum

AUGUST 4, 2022

AR has developed enormously over the last few years, meaning that highly visual step-by-step guidance and training procedures can be delivered to employees to ensure they follow safety protocols without being exposed to actual real-life risks in the manufacturing facility. She joined NSF in 2017. appeared first on.

Recruitment 98

Recruitment Pharma Training Pharmaceutical manufacturing 98

Pharmaceutical Technology

FEBRUARY 24, 2023

The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact. The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years.

Pharma 64

Pharma Medicine Competition Marketing 64

European Pharmaceutical Review

FEBRUARY 7, 2023

In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. Edward helps clients with compliance and safety issues, including in the development, launch and marketing of new products.

Medical 117

Medical Government Marketing Medicine 117

Pharmaceutical Technology

MARCH 24, 2023

Currently, 40 biosimilars are FDA-approved and 25 have launched, whereas the EMA has approved 86 biosimilars since 2006. Further, there remains scepticism on the efficacy and safety of biosimilars. Patients may be reluctant to switch to biosimilars and doctors may have limited incentives to choose biosimilars.

Competition 59

Competition Marketing FDA Physicians 59

Pharmaceutical Technology

NOVEMBER 24, 2022

Translational Pharmaceutics integrates drug substance, drug product, and clinical testing activities, including human ADME and radiolabeling, under a single organization to accelerate timelines and reduce costs, which ultimately gets new medicines to patients faster. Conclusion. To find out more, visit: [link].

Manufacturing 52

Manufacturing Pharmaceutical Specialization Medicine 52

Pharmaceutical Technology

AUGUST 26, 2008

.” By the early 2000s AstraZeneca had already realised the critical importance of biotechnology, making a number of strategic investments in biotech companies, Abgenix in 2003, Cambridge Antibody Technology in 2006 and culminating in its acquisition of US biotech firm, Medimmune in April 2007 for £15bn.

Pharmaceutical 40

Pharmaceutical Manufacturing Biopharma Medicine 40

World of DTC Marketing

DECEMBER 10, 2020

SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Say goodbye to all the supposed goodwill.

Insurance 181

Insurance Pharma Manufacturing Retail 181

World of DTC Marketing

MAY 6, 2021

Some commercially insured patients who pay only prescription drug copayments appear to be insulated from increases in drug prices. However, more than half of patients pay deductibles or coinsurance and may experience substantial increases in out-of-pocket spending when drug prices increase.

Pharma 185

Pharma Food and Drug Administration Government Insurance 185